Cardiovascular benefits of evolocumab


  • The BMJ
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Evolocumab reduced the risk of major cardiovascular events by 15% in patients with atherosclerotic cardiovascular disease who were already taking statins, a study has found.

The study randomised 27 564 patients with clinically evident atherosclerotic cardiovascular disease to evolocumab (either...